Ventyx Biosciences Inc

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics targeting inflammation in cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's NLRP3 inhibitor portfolio includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease; Tamuzimod, a sphingosine 1 phosphate receptor modulator in Phase II trials for ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor for cryopyrin-associated periodic syndrome. It is also developing VTX3232, a CNS-penetrant NLRP3 inhibitor in a Phase 2a trial for early Parkinson's disease and a Phase 2 trial for obesity with additional cardiovascular risk factors. Incorporated in 2018 and headquartered in San Diego, California, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company as of March 4, 2026.